OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
OKYO Pharma (NASDAQ: OKYO) announced that CEO Gary S. Jacob will present at the 4th Annual GPCRs-Targeted Drug Discovery Summit in Boston on May 22, 2025. The presentation will focus on the development of urcosimod, the company's lead clinical drug candidate for treating neuropathic corneal pain (NCP).
NCP is a debilitating condition affecting tens of thousands worldwide, characterized by chronic, severe eye discomfort. Currently, there is no FDA-approved therapy for this condition. The presentation will take place at the Revere Hotel Boston Common and will detail urcosimod's targeting of CMKLR1 (ChemR23) for NCP treatment.
OKYO Pharma (NASDAQ: OKYO) ha annunciato che il CEO Gary S. Jacob presenterà al 4° Summit Annuale sulla Scoperta di Farmaci Mirati ai GPCR che si terrà a Boston il 22 maggio 2025. La presentazione sarà incentrata sullo sviluppo di urcosimod, il principale candidato farmaco clinico dell'azienda per il trattamento del dolore corneale neuropatico (NCP).
Il NCP è una condizione debilitante che colpisce decine di migliaia di persone in tutto il mondo, caratterizzata da un fastidio oculare cronico e severo. Attualmente non esistono terapie approvate dalla FDA per questa patologia. La presentazione si svolgerà presso il Revere Hotel Boston Common e illustrerà il meccanismo di azione di urcosimod, che mira a CMKLR1 (ChemR23) per il trattamento del NCP.
OKYO Pharma (NASDAQ: OKYO) anunció que el CEO Gary S. Jacob presentará en la 4ª Cumbre Anual sobre Descubrimiento de Fármacos Dirigidos a GPCR en Boston el 22 de mayo de 2025. La presentación se centrará en el desarrollo de urcosimod, el principal candidato clínico de la compañía para tratar el dolor corneal neuropático (NCP).
El NCP es una condición debilitante que afecta a decenas de miles de personas en todo el mundo, caracterizada por un malestar ocular crónico y severo. Actualmente, no existe ninguna terapia aprobada por la FDA para esta condición. La presentación tendrá lugar en el Revere Hotel Boston Common y detallará cómo urcosimod se dirige a CMKLR1 (ChemR23) para el tratamiento del NCP.
OKYO Pharma (NASDAQ: OKYO)는 CEO Gary S. Jacob이 2025년 5월 22일 보스턴에서 열리는 제4회 연례 GPCR 표적 신약 개발 서밋에서 발표할 것이라고 발표했습니다. 발표는 회사의 주요 임상 후보 약물인 우르코시모드의 신경병증성 각막 통증(NCP) 치료 개발에 중점을 둘 예정입니다.
NCP는 전 세계 수만 명에게 영향을 미치는 심각한 만성 안구 통증 질환으로, 현재 FDA 승인 치료제가 없습니다. 발표는 Revere Hotel Boston Common에서 진행되며, NCP 치료를 위한 CMKLR1(ChemR23)을 표적으로 하는 우르코시모드의 작용 기전을 상세히 설명할 것입니다.
OKYO Pharma (NASDAQ : OKYO) a annoncé que son PDG, Gary S. Jacob, présentera lors du 4e Sommet Annuel sur la Découverte de Médicaments Ciblant les GPCR à Boston le 22 mai 2025. La présentation portera sur le développement de l'urcosimod, le principal candidat médicament clinique de la société pour le traitement de la douleur cornéenne neuropathique (NCP).
La NCP est une affection invalidante qui touche des dizaines de milliers de personnes dans le monde, caractérisée par une douleur oculaire chronique et sévère. Actuellement, il n'existe aucun traitement approuvé par la FDA pour cette maladie. La présentation se tiendra au Revere Hotel Boston Common et détaillera la cible de l'urcosimod, le CMKLR1 (ChemR23), pour le traitement de la NCP.
OKYO Pharma (NASDAQ: OKYO) gab bekannt, dass CEO Gary S. Jacob auf dem 4. jährlichen GPCRs-Targeted Drug Discovery Summit am 22. Mai 2025 in Boston sprechen wird. Die Präsentation wird sich auf die Entwicklung von Urcosimod konzentrieren, dem führenden klinischen Medikamentenkandidaten des Unternehmens zur Behandlung von neuropathischen Hornhautschmerzen (NCP).
NCP ist eine schwere Erkrankung, die weltweit Zehntausende betrifft und sich durch chronische, starke Augenschmerzen auszeichnet. Derzeit gibt es keine von der FDA zugelassene Therapie für diese Erkrankung. Die Präsentation findet im Revere Hotel Boston Common statt und erläutert die Wirkweise von Urcosimod, das auf CMKLR1 (ChemR23) zur Behandlung von NCP abzielt.
- None.
- None.
LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announced that its CEO, Gary S. Jacob, Ph.D., will be giving an oral presentation at the 4th Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on May 22, 2025. Dr. Jacob’s presentation will cover the development of urcosimod, OKYO’s lead clinical drug candidate, to treat neuropathic corneal pain (NCP) which is a debilitating condition affecting many tens of thousands worldwide, and is characterized by chronic, severe eye discomfort.
Presentation Information:
Event: 4th Annual GPCRs-Targeted Drug Discovery Summit
Presenter: Dr. Gary S. Jacob, CEO of OKYO Pharma
Presentation Title: Clinical Development of Urcosimod, Targeting CMKLR1 (ChemR23), to Treat Neuropathic Corneal Pain
Date: Thursday, May 22, 2025
Location: Revere Hotel Boston Common, Boston, MA
About Neuropathic Corneal Pain (NCP)
NCP is a condition that causes severe pain and sensitivity of the eyes, face, or head. The exact cause of NCP is unknown but is thought to result from nerve damage to the cornea combined with inflammation. NCP, which can exhibit as a severe, chronic, debilitating condition in patients suffering from a host of ophthalmic conditions, is presently treated, with limited success, by various topical and systemic treatments in an off-label fashion.
About Urcosimod (formerly called OK-101)
Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain, respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to potentially enhance the residence time of urcosimod within the ocular environment. Urcosimod showed clear statistical significance in multiple endpoints in a 240-patient Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease, and is presently being evaluated in a just-completed randomized, placebo-controlled, double-masked Phase 2 trial involving 17 neuropathic corneal pain patients.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain and dry eye disease, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and ocular diseases. In addition to the completed Phase 2 trial of urcosimod to treat dry eye disease patients, OKYO is also currently evaluating urcosimod to treat neuropathic corneal pain patients in a Phase 2 trial.
For further information, please visit www.okyopharma.com.
Enquiries:
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | 917-497-7560 |
| Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
FAQ
What will OKYO Pharma present at the GPCRs-Targeted Drug Discovery Summit in May 2025?
What condition is OKYO Pharma's urcosimod designed to treat?
When and where will OKYO Pharma's presentation take place?
How many people are affected by neuropathic corneal pain (NCP)?
